Vanguard Group Inc Nuvalent, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,439,838 shares of NUVL stock, worth $331 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,439,838
Previous 4,499,864
1.33%
Holding current value
$331 Million
Previous $352 Million
10.61%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding NUVL
# of Institutions
216Shares Held
60.9MCall Options Held
319KPut Options Held
211K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.34 Billion32.3% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$393 Million19.15% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$226 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$138 Million12.88% of portfolio
-
Perceptive Advisors LLC New York, NY1.63MShares$122 Million4.85% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.21B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...